生物制剂依从性对类风湿关节炎治疗达标的影响
|
摘要
达标治疗是类风湿关节炎(RA)治疗的重要策略,用药依从性是影响RA达标治疗的重要因素,其中生物制剂依从性差是我国RA患者总体达标率低的重要因素。影响RA患者生物制剂依从性的因素包括缺乏疗效、药物不良反应、治疗体验、合并用药以及患者的年龄、性别、收入、工作强度等。应通过增加患者的依从性尤其是生物制剂的依从性,提高RA患者的治疗达标率,改善患者的生活质量和预后。
Treat to target is the most important strategy for rheumatoid arthritis(RA) management. Drug adherence is critical for treating RA to target, of which non-adherence of biologics is one of the important reasons for low target-achieving rate in Chinese RA patients. The associated factors of biologics non-adherence in RA include loss of effectiveness, adverse effect, treatment experience, drug combination, age, gender, income and working intensity. Improvement of drug adherence especially biologics adherence will increase the target-achieving rate, life quality and prognosis of RA patients.
Treat to target is the most important strategy for rheumatoid arthritis(RA) management. Drug adherence is critical for treating RA to target, of which non-adherence of biologics is one of the important reasons for low target-achieving rate in Chinese RA patients. The associated factors of biologics non-adherence in RA include loss of effectiveness, adverse effect, treatment experience, drug combination, age, gender, income and working intensity. Improvement of drug adherence especially biologics adherence will increase the target-achieving rate, life quality and prognosis of RA patients.
引文
[1]中华医学会风湿病学分会. 2018中国类风湿关节炎诊疗指南.中华内科杂志, 2018, 57(4):242-251.
[2]Gossec L, Molto A, Romand X, Puyraimond-Zemmour D,Lavielle M, Beauvais C, Senbel E, Flipo RM, Pouplin S,Richez C, Saraux A, Méziéres M, Gutermann L, Gaudin P,Wendling D, Dougados M. Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases:a process based on literature reviews and expert consensus. Joint Bone Spine, 2019,86(1):13-19.
[3]Rantalaiho V, Kautiainen H, Korpela M, Puolakka K, Bl?field H, Ilva K, Hannonen P, Leirisalo-Repo M, M?tt?nen T; FINRACo Study Group. Physicians’ adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis:a subanalysis of the FIN-RACo trial. Ann Rheum Dis, 2014, 73(4):788-790.
[4]Smolen JS, LandewéR, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M,van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, GomezReino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T,Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2016 update. Ann Rheum Dis, 2017, 76(6):960-977.
[5]Wang GY, Zhang SL, Wang XR, Feng M, Li C, An Y, Li XF,Wang LZ, Wang CH, Wang YF, Yang R, Yan HM, Wang GC,Lu X, Liu X, Zhu P, Chen LN, Jin HT, Liu JT, Guo HF, Chen HY, Xie JL, Wei P, Wang JX, Liu XY, Sun L, Cui LF, Shu R, Liu BL, Yu P, Zhang ZL, Li GT, Li ZB, Yang J, Li JF, Jia B, Zhang FX, Tao JM, Lin JY, Wei MQ, Liu XM, Ke D, Hu SX, Ye C, Han SL, Yang XY, Li H, Huang CB, Gao M, Lai B,Cheng YJ, Li XF, Song LJ, Yu XX, Wang AX, Wu LJ, Wang YH, He L, Sun WW, Gong L, Wang XY, Wang Y, Zhao Y,Li XX, Wang Y, Zhang Y, Su Y, Zhang CF, Mu R, Li ZG.Remission of rheumatoid arthritis and potential determinants:a national multi-center cross-sectional survey. Clin Rheumatol,2015, 34(2):221-230.
[6]Jin S, Li M, Fang Y, Li Q, Liu J, Duan X, Liu Y, Wu R, Shi X, Wang Y, Jiang Z, Wang Y, Yu C, Wang Q, Tian X, Zhao Y, Zeng X; CREDIT Co-authors. Chinese registry of rheumatoid arthritis(CREDIT):Ⅱ. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis. Arthritis Res Ther, 2017, 19(1):251.
[7]Kyburz D, Gabay C, Michel BA, Finckh A; physicians of SCQM-RA. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression:a population-based cohort study. Rheumatology(Oxford), 2011, 50(6):1106-1110.
[8]Aletaha D, Alasti F, Smolen JS. Optimisation of a treat-to-target approach in rheumatoid arthritis:strategies for the 3-month time point. Ann Rheum Dis, 2016, 75(8):1479-1485.
[9]Gadallah MA, Boulos DN, Gebrel A, Dewedar S, Morisky DE. Assessment of rheumatoid arthritis patients’ adherence to treatment. Am J Med Sci, 2015, 349(2):151-156.
[10]Li L, Cui Y, Yin R, Chen S, Zhao Q, Chen H, Shen B.Medication adherence has an impact on disease activity in rheumatoid arthritis:a systematic review and meta-analysis. Patient Prefer Adherence, 2017, 11:1343-1356.
[11]Xia Y, Yin R, Fu T, Zhang L, Zhang Q, Guo G, Li L, Gu Z.Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis. Patient Prefer Adherence, 2016, 10:735-742.
[12]莫颖倩,毕瑜斐,戴冽,Pierre Miossec. IL-17在局部及全身的致关节炎作用:从发现到靶向治疗.新医学, 2018, 49(7):461-467.
[13]Yoshida K, Tokuda Y, Oshikawa H, Utsunomiya M, Kobayashi T, Kimura M, Deshpande GA, Matsui K, Kishimoto M. An observational study of tocilizumab and TNF-alpha inhibitor use in a Japanese community hospital:different remission rates,similar drug survival and safety. Rheumatology(Oxford), 2011,50(11):2093-2099.
[14]Leon L, Rodriguez-Rodriguez L, Rosales Z, Gomez A, Lamas JR, Pato E, Jover JA, Abasolo L. Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice. Scand J Rheumatol, 2016, 45(6):456-460.
[15]Strand V, Greenberg JD, Griffith J, Bao Y, Saunders KC, Garg V, Li G, Ganguli A. Impact of treatment with biologic agents on the use of mechanical devices among rheumatoid arthritis patients in a large US patient registry. Arthritis Care Res(Hoboken), 2016, 68(7):914-921.
[16]Bluett J, Morgan C, Thurston L, Plant D, Hyrich KL,Morgan AW, Wilson AG, Isaacs JD, Cordingley L, Barton A; BRAGGSS. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs:results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology(Oxford),2015, 54(3):494-499.
[17]Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M, Brouwer E, Bos R, Lems WF, Colin EM, Allaart CF, Meek IL, LandewéR,Bernelot Moens HJ, van Riel PL, van de Laar MA, Jansen TL; Dutch National POET Collaboration. Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity:a pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol, 2016, 68(8):1810-1817.
[18]Campbell NKJ, Saadeldin K, De Vera MA. The duality of economic issues with medication non-adherence in patients with inflammatory arthritis. Curr Rheumatol Rep, 2017, 19(10):66.
[19]Lathia U, Ewara EM, Nantel F. Impact of adherence to biological agents on health care resource utilization for patients over the age of 65 years with rheumatoid arthritis. Patient Prefer Adherence, 2017, 11:1133-1142.
[20]Favalli EG, Sinigaglia L, Becciolini A, Grosso V, Gorla R,Bazzani C, Atzeni F, Sarzi Puttini PC, Fusaro E, Pellerito R, Caporali R. Two-year persistence of golimumab as secondline biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors:real-life data from the LORHEN registry. Int J Rheum Dis, 2018, 21(2):422-430.
[21]Ebina K, Hashimoto M, Yamamoto W, Ohnishi A, Kabata D,Hirano T, Hara R, Katayama M, Yoshida S, Nagai K, Son Y, Amuro H, Akashi K, Fujimura T, Hirao M, Yamamoto K,Shintani A, Kumanogoh A, Yoshikawa H. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis-The ANSWER cohort study. PLoS One,2018, 13(3):e0194130.
[22]Calvo-Alén J, Monteagudo I, Salvador G, Vázquez-Rodríguez TR, Tovar-Beltrán JV, Vela P, Maceiras F, Bustabad S,Román-Ivorra JA, Díaz-Miguel C, Rosas J, Raya E, Carmona L, Cea-Calvo L, Arteaga MJ, Fernández S, Marras C. Nonadherence to subcutaneous biological medication in patients with rheumatoid arthritis:a multicentre, non-interve-ntional study.Clin Exp Rheumatol, 2017, 35(3):423-430.
[23]Bhoi P, Bessette L, Bell MJ, Tkaczyk C, Nantel F, Maslova K.Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis:analysis from a Canadian administrative database. BMJ Open,2017, 7(9):e015872.
[24]Poulos C, Hauber AB, Gonzalez JM, Turpcu A. Patients’willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. Arthritis Care Res(Hoboken),2014, 66(7):1008-1015.
[25]Bolge SC, Goren A, Tandon N. Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis:a patient perspective. Patient Prefer Adherence, 2015,9:121-131.
[26]Dehoratius RJ, Brent LH, Curtis JR, Ellis LA, Tang KL.Satisfaction with subcutaneous golimumab and its auto-injector among rheumatoid arthritis patients with inadequate response to Adalimumab or Etanercept. Patient. 2018, 11(3):361-369.
[27]Okazaki M, Kobayashi H, Shimizu H, Ishii Y, Yajima T,Kanbori M. Safety, Effectiveness, and treatment persistence of golimumab in elderly patients with rheumatoid arthritis in realworld clinical practice in Japan. Rheumatol Ther, 2018, 5(1):135-148.
[28]Iannone F, Santo L, Anelli MG, Bucci R, Semeraro A, Quarta L,D’Onofrio F, Marsico A, Carlino G, Casilli O, Cacciapaglia F,Zuccaro C, Falappone PC, Cantatore FP, Muratore M, Lapadula G.Golimumab in real-life settings:2 years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthr-itis Rheum, 2017, 47(1):108-114.
[29]Zhang L, Lu GH, Ye S, Wu B, Shen Y, Li T. Treatment adherence and disease burden of individuals with rheumatic diseases admitted as outpatients to a large rheumatology center in Shanghai, China. Patient Prefer Adherence, 2017, 11:1591-1601.
[2]Gossec L, Molto A, Romand X, Puyraimond-Zemmour D,Lavielle M, Beauvais C, Senbel E, Flipo RM, Pouplin S,Richez C, Saraux A, Méziéres M, Gutermann L, Gaudin P,Wendling D, Dougados M. Recommendations for the assessment and optimization of adherence to disease-modifying drugs in chronic inflammatory rheumatic diseases:a process based on literature reviews and expert consensus. Joint Bone Spine, 2019,86(1):13-19.
[3]Rantalaiho V, Kautiainen H, Korpela M, Puolakka K, Bl?field H, Ilva K, Hannonen P, Leirisalo-Repo M, M?tt?nen T; FINRACo Study Group. Physicians’ adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis:a subanalysis of the FIN-RACo trial. Ann Rheum Dis, 2014, 73(4):788-790.
[4]Smolen JS, LandewéR, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M,van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, GomezReino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T,Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2016 update. Ann Rheum Dis, 2017, 76(6):960-977.
[5]Wang GY, Zhang SL, Wang XR, Feng M, Li C, An Y, Li XF,Wang LZ, Wang CH, Wang YF, Yang R, Yan HM, Wang GC,Lu X, Liu X, Zhu P, Chen LN, Jin HT, Liu JT, Guo HF, Chen HY, Xie JL, Wei P, Wang JX, Liu XY, Sun L, Cui LF, Shu R, Liu BL, Yu P, Zhang ZL, Li GT, Li ZB, Yang J, Li JF, Jia B, Zhang FX, Tao JM, Lin JY, Wei MQ, Liu XM, Ke D, Hu SX, Ye C, Han SL, Yang XY, Li H, Huang CB, Gao M, Lai B,Cheng YJ, Li XF, Song LJ, Yu XX, Wang AX, Wu LJ, Wang YH, He L, Sun WW, Gong L, Wang XY, Wang Y, Zhao Y,Li XX, Wang Y, Zhang Y, Su Y, Zhang CF, Mu R, Li ZG.Remission of rheumatoid arthritis and potential determinants:a national multi-center cross-sectional survey. Clin Rheumatol,2015, 34(2):221-230.
[6]Jin S, Li M, Fang Y, Li Q, Liu J, Duan X, Liu Y, Wu R, Shi X, Wang Y, Jiang Z, Wang Y, Yu C, Wang Q, Tian X, Zhao Y, Zeng X; CREDIT Co-authors. Chinese registry of rheumatoid arthritis(CREDIT):Ⅱ. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis. Arthritis Res Ther, 2017, 19(1):251.
[7]Kyburz D, Gabay C, Michel BA, Finckh A; physicians of SCQM-RA. The long-term impact of early treatment of rheumatoid arthritis on radiographic progression:a population-based cohort study. Rheumatology(Oxford), 2011, 50(6):1106-1110.
[8]Aletaha D, Alasti F, Smolen JS. Optimisation of a treat-to-target approach in rheumatoid arthritis:strategies for the 3-month time point. Ann Rheum Dis, 2016, 75(8):1479-1485.
[9]Gadallah MA, Boulos DN, Gebrel A, Dewedar S, Morisky DE. Assessment of rheumatoid arthritis patients’ adherence to treatment. Am J Med Sci, 2015, 349(2):151-156.
[10]Li L, Cui Y, Yin R, Chen S, Zhao Q, Chen H, Shen B.Medication adherence has an impact on disease activity in rheumatoid arthritis:a systematic review and meta-analysis. Patient Prefer Adherence, 2017, 11:1343-1356.
[11]Xia Y, Yin R, Fu T, Zhang L, Zhang Q, Guo G, Li L, Gu Z.Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis. Patient Prefer Adherence, 2016, 10:735-742.
[12]莫颖倩,毕瑜斐,戴冽,Pierre Miossec. IL-17在局部及全身的致关节炎作用:从发现到靶向治疗.新医学, 2018, 49(7):461-467.
[13]Yoshida K, Tokuda Y, Oshikawa H, Utsunomiya M, Kobayashi T, Kimura M, Deshpande GA, Matsui K, Kishimoto M. An observational study of tocilizumab and TNF-alpha inhibitor use in a Japanese community hospital:different remission rates,similar drug survival and safety. Rheumatology(Oxford), 2011,50(11):2093-2099.
[14]Leon L, Rodriguez-Rodriguez L, Rosales Z, Gomez A, Lamas JR, Pato E, Jover JA, Abasolo L. Long-term drug survival of biological agents in patients with rheumatoid arthritis in clinical practice. Scand J Rheumatol, 2016, 45(6):456-460.
[15]Strand V, Greenberg JD, Griffith J, Bao Y, Saunders KC, Garg V, Li G, Ganguli A. Impact of treatment with biologic agents on the use of mechanical devices among rheumatoid arthritis patients in a large US patient registry. Arthritis Care Res(Hoboken), 2016, 68(7):914-921.
[16]Bluett J, Morgan C, Thurston L, Plant D, Hyrich KL,Morgan AW, Wilson AG, Isaacs JD, Cordingley L, Barton A; BRAGGSS. Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs:results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology(Oxford),2015, 54(3):494-499.
[17]Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M, Brouwer E, Bos R, Lems WF, Colin EM, Allaart CF, Meek IL, LandewéR,Bernelot Moens HJ, van Riel PL, van de Laar MA, Jansen TL; Dutch National POET Collaboration. Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity:a pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol, 2016, 68(8):1810-1817.
[18]Campbell NKJ, Saadeldin K, De Vera MA. The duality of economic issues with medication non-adherence in patients with inflammatory arthritis. Curr Rheumatol Rep, 2017, 19(10):66.
[19]Lathia U, Ewara EM, Nantel F. Impact of adherence to biological agents on health care resource utilization for patients over the age of 65 years with rheumatoid arthritis. Patient Prefer Adherence, 2017, 11:1133-1142.
[20]Favalli EG, Sinigaglia L, Becciolini A, Grosso V, Gorla R,Bazzani C, Atzeni F, Sarzi Puttini PC, Fusaro E, Pellerito R, Caporali R. Two-year persistence of golimumab as secondline biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors:real-life data from the LORHEN registry. Int J Rheum Dis, 2018, 21(2):422-430.
[21]Ebina K, Hashimoto M, Yamamoto W, Ohnishi A, Kabata D,Hirano T, Hara R, Katayama M, Yoshida S, Nagai K, Son Y, Amuro H, Akashi K, Fujimura T, Hirao M, Yamamoto K,Shintani A, Kumanogoh A, Yoshikawa H. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis-The ANSWER cohort study. PLoS One,2018, 13(3):e0194130.
[22]Calvo-Alén J, Monteagudo I, Salvador G, Vázquez-Rodríguez TR, Tovar-Beltrán JV, Vela P, Maceiras F, Bustabad S,Román-Ivorra JA, Díaz-Miguel C, Rosas J, Raya E, Carmona L, Cea-Calvo L, Arteaga MJ, Fernández S, Marras C. Nonadherence to subcutaneous biological medication in patients with rheumatoid arthritis:a multicentre, non-interve-ntional study.Clin Exp Rheumatol, 2017, 35(3):423-430.
[23]Bhoi P, Bessette L, Bell MJ, Tkaczyk C, Nantel F, Maslova K.Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis:analysis from a Canadian administrative database. BMJ Open,2017, 7(9):e015872.
[24]Poulos C, Hauber AB, Gonzalez JM, Turpcu A. Patients’willingness to trade off between the duration and frequency of rheumatoid arthritis treatments. Arthritis Care Res(Hoboken),2014, 66(7):1008-1015.
[25]Bolge SC, Goren A, Tandon N. Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis:a patient perspective. Patient Prefer Adherence, 2015,9:121-131.
[26]Dehoratius RJ, Brent LH, Curtis JR, Ellis LA, Tang KL.Satisfaction with subcutaneous golimumab and its auto-injector among rheumatoid arthritis patients with inadequate response to Adalimumab or Etanercept. Patient. 2018, 11(3):361-369.
[27]Okazaki M, Kobayashi H, Shimizu H, Ishii Y, Yajima T,Kanbori M. Safety, Effectiveness, and treatment persistence of golimumab in elderly patients with rheumatoid arthritis in realworld clinical practice in Japan. Rheumatol Ther, 2018, 5(1):135-148.
[28]Iannone F, Santo L, Anelli MG, Bucci R, Semeraro A, Quarta L,D’Onofrio F, Marsico A, Carlino G, Casilli O, Cacciapaglia F,Zuccaro C, Falappone PC, Cantatore FP, Muratore M, Lapadula G.Golimumab in real-life settings:2 years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthr-itis Rheum, 2017, 47(1):108-114.
[29]Zhang L, Lu GH, Ye S, Wu B, Shen Y, Li T. Treatment adherence and disease burden of individuals with rheumatic diseases admitted as outpatients to a large rheumatology center in Shanghai, China. Patient Prefer Adherence, 2017, 11:1591-1601.